BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 38058264)

  • 1. Disulfidptosis-related PABPC3 promotes tumor progression and inhibits immune activity in osteosarcoma.
    Cao Y; Wu S; Gu Y; Wong YH; Shi Y; Zhang L
    J Gene Med; 2024 Jan; 26(1):e3641. PubMed ID: 38058264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptome and single-cell analysis reveal disulfidptosis-related modification patterns of tumor microenvironment and prognosis in osteosarcoma.
    Wang L; Liu Y; Tai J; Dou X; Yang H; Li Q; Liu J; Yan Z; Liu X
    Sci Rep; 2024 Apr; 14(1):9186. PubMed ID: 38649690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel disulfidptosis-associated expression pattern in breast cancer based on machine learning.
    Wang Z; Du X; Lian W; Chen J; Hong C; Li L; Chen D
    Front Genet; 2023; 14():1193944. PubMed ID: 37456667
    [No Abstract]   [Full Text] [Related]  

  • 4. Identification of disulfidptosis-related subgroups and prognostic signatures in lung adenocarcinoma using machine learning and experimental validation.
    Wang Y; Xu Y; Liu C; Yuan C; Zhang Y
    Front Immunol; 2023; 14():1233260. PubMed ID: 37799714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and validation of disulfidptosis-associated molecular clusters in non-alcoholic fatty liver disease.
    Yu X; Guo Z; Fang Z; Yang K; Liu C; Dong Z; Liu C
    Front Genet; 2023; 14():1251999. PubMed ID: 37745847
    [No Abstract]   [Full Text] [Related]  

  • 6. Development and validation of a disulfidptosis and M2 TAM-related classifier for bladder cancer to explore tumor subtypes, immune landscape and drug treatment.
    Ren C; Wang Q; Xu Z; Pan Y; Li Y; Liu X
    J Cancer Res Clin Oncol; 2023 Nov; 149(17):15805-15818. PubMed ID: 37668798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of disulfidptosis-related subtypes and development of a prognosis model based on stacking framework in renal clear cell carcinoma.
    Peng K; Wang N; Liu Q; Wang L; Duan X; Xie G; Li J; Ding D
    J Cancer Res Clin Oncol; 2023 Nov; 149(15):13793-13810. PubMed ID: 37530800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Machine learning identification and immune infiltration of disulfidptosis-related Alzheimer's disease molecular subtypes.
    Zhu Y; Kong L; Han T; Yan Q; Liu J
    Immun Inflamm Dis; 2023 Oct; 11(10):e1037. PubMed ID: 37904698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diverse cell death patterns-related signature for predicting prognosis and drug sensitivity of osteosarcoma patients.
    Shi Y; Wu S; Zhang X; Cao Y; Zhang L
    J Gene Med; 2024 Jan; 26(1):e3613. PubMed ID: 37861176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of disulfidptosis-associated clusters on breast cancer survival rates and guiding personalized treatment.
    Chen X; Hu G; Yu Q
    Front Endocrinol (Lausanne); 2023; 14():1256132. PubMed ID: 38116315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unraveling the role of disulfidptosis-related LncRNAs in colon cancer: a prognostic indicator for immunotherapy response, chemotherapy sensitivity, and insights into cell death mechanisms.
    Chi H; Huang J; Yan Y; Jiang C; Zhang S; Chen H; Jiang L; Zhang J; Zhang Q; Yang G; Tian G
    Front Mol Biosci; 2023; 10():1254232. PubMed ID: 37916187
    [No Abstract]   [Full Text] [Related]  

  • 12. Leveraging a disulfidptosis-related signature to predict the prognosis and immunotherapy effectiveness of cutaneous melanoma based on machine learning.
    Zhao Y; Wei Y; Fan L; Nie Y; Li J; Zeng R; Li J; Zhan X; Lei L; Kang Z; Li J; Zhang W; Yang Z
    Mol Med; 2023 Oct; 29(1):145. PubMed ID: 37884883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification a unique disulfidptosis classification regarding prognosis and immune landscapes in thyroid carcinoma and providing therapeutic strategies.
    Feng Z; Zhao Q; Ding Y; Xu Y; Sun X; Chen Q; Zhang Y; Miao J; Zhu J
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11157-11170. PubMed ID: 37347261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Disulfidptosis-Related Gene Signature Associated with Prognosis and Immune Cell Infiltration in Osteosarcoma.
    Chen P; Shen J
    Bioengineering (Basel); 2023 Sep; 10(10):. PubMed ID: 37892851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioinformatics-based analysis of the relationship between disulfidptosis and prognosis and treatment response in pancreatic cancer.
    Xiong Y; Kong X; Mei H; Wang J; Zhou S
    Sci Rep; 2023 Dec; 13(1):22218. PubMed ID: 38097783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction of a novel disulfidptosis-related signature for improving outcomes in hepatocellular carcinoma: Observational study.
    Chen X; Liang Q; Zhou Y
    Medicine (Baltimore); 2023 Oct; 102(40):e35423. PubMed ID: 37800779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of a disulfidptosis-related scoring system to predict clinical outcome and immunotherapy response in acute myeloid leukemia by integrated analysis of single-cell and bulk RNA-sequencing.
    Zhong F; Jiang J; Yao FY; Liu J; Shuai X; Wang XL; Huang B; Wang X
    Front Pharmacol; 2023; 14():1272701. PubMed ID: 38053840
    [No Abstract]   [Full Text] [Related]  

  • 18. A novel prognostic signature and immune microenvironment characteristics associated with disulfidptosis in papillary thyroid carcinoma based on single-cell RNA sequencing.
    Liao Z; Cheng Y; Zhang H; Jin X; Sun H; Wang Y; Yan J
    Front Cell Dev Biol; 2023; 11():1308352. PubMed ID: 38033866
    [No Abstract]   [Full Text] [Related]  

  • 19. A disulfidptosis-related lncRNA prognostic model to predict survival and response to immunotherapy in lung adenocarcinoma.
    Zhang HB; Pan JY; Zhu T
    Front Pharmacol; 2023; 14():1254119. PubMed ID: 37822882
    [No Abstract]   [Full Text] [Related]  

  • 20. Single-cell sequencing and bulk RNA data reveal the tumor microenvironment infiltration characteristics of disulfidptosis related genes in breast cancer.
    Chen Y; Jin C; Cui J; Diao Y; Wang R; Xu R; Yao Z; Wu W; Li X
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):12145-12164. PubMed ID: 37428249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.